Altre lingue Sarepta Therapeutics, Inc.

Azioni

SRPT

US8036071004

Tempo reale stimato Cboe BZX Altri mercati azionari 18:30:36 04/06/2024			Variaz. 5gg	Var. 1 gen.
121,1 ^USD	-2,54%		+6,50%	+25,17%

30/05	Aggiornamento settoriale: titoli del settore sanitario misti prima della campanella giovedì	MT
30/05	Aggiornamento settoriale: Assistenza sanitaria	MT

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to S&P 1000	03/06
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to S&P 400 - Biotechnology	03/06
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to S&P 400 Health Care	03/06
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to S&P Composite 1500	03/06
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to S&P 400	03/06
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	31/05
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	30/05
Sector Update: Health Care	30/05
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Ahead of Key Inflation Data	30/05
Sarepta Therapeutics to Replace Shockwave Medical in S&P MidCap 400	30/05
Sarepta Therapeutics Shares Fall After RBC Downgrade	28/05
Sarepta Therapeutics : P.413-251 Seo et al. In situ biodistribution & localization of SRP-9003 in LGMD2ER4 Mice	10/05
Sarepta Therapeutics - Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health	06/05
Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health	03/05
Sarepta Therapeutics to Benefit as Regulatory Review on DMD Therapy Picks Up, Morgan Stanley Says	02/05
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q1 EPS $0.73, vs. Street Est of $0.30	01/05
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q1 Revenue $413.5M, vs. Street Est of $370.5M	01/05
Sarepta Therapeutics Swings to Q1 Adjusted Earnings as Revenue Increases -- Shares Rise After Hours	01/05
Sarepta Therapeutics: Q1 Earnings Snapshot	01/05
Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments	01/05

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Sarepta Therapeutics, Inc.

Azioni

SRPT

US8036071004

Altre lingue

Filtri